Monte Rosa Therapeutics, Inc. (GLUE) Stock Analysis
Monte Rosa Therapeutics, Inc. (GLUE) Stock Analysis
Overall Grade: F (Concerning)
View interactive company profile →
Monte Rosa Therapeutics, Inc. faces challenges in financial performance that warrant careful analysis.
Key Metrics:
| Metric | Value | Context |
|---|---|---|
| ROIC | 2.6% | Below expectations |
| FCF Margin | 79.9% | Strong cash generation |
| Debt/Equity | 0.0x | Conservative leverage |
Investment Thesis: Healthy free cash flow margin of 79.9% provides financial flexibility for growth and shareholder returns.
What is Monte Rosa Therapeutics, Inc.'s Profitability and ROIC?
Monte Rosa Therapeutics, Inc.'s return on invested capital of 2.6% is below the typical cost of capital.
Key Metrics
| Metric | Value | Rating | Interpretation |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 2.6% | Red flag | Below cost of capital |
| Return on Equity (ROE) | 8.4% | Adequate | Moderate equity returns |
| Operating Margin | 4.7% | Warning | Moderate operational efficiency |
How Strong is Monte Rosa Therapeutics, Inc.'s Cash Flow Quality?
Monte Rosa Therapeutics, Inc. generated $145.0M in free cash flow over the trailing twelve months, representing a 79.9% margin. Cash earnings quality is strong, with operating cash flow exceeding net income by 7.1x.
Key Metrics
| Metric | Value | Rating | Interpretation |
|---|---|---|---|
| Free Cash Flow Margin | 79.9% | Excellent | Excellent cash conversion |
| Free Cash Flow (TTM) | $145.0M | Good | Positive cash generation |
| OCF/Net Income | 7.1x | Excellent | High earnings quality |
| FCF Consistency (8Q) | N/A | Warning | Variable cash flow |
What is Monte Rosa Therapeutics, Inc.'s Financial Health?
Monte Rosa Therapeutics, Inc.'s debt-to-equity ratio of 0.0x indicates conservative leverage.
Key Metrics
| Metric | Value | Rating | Interpretation |
|---|---|---|---|
| Debt to Equity | 0.0x | Excellent | Conservative capital structure |
Is Monte Rosa Therapeutics, Inc. Stock Overvalued or Undervalued?
Monte Rosa Therapeutics, Inc. trades at a P/E of 29.1x, representing a premium to the sector median of N/A. Free cash flow yield of 23.8% offers attractive cash returns.
Key Metrics
| Metric | Value | Rating | Interpretation |
|---|---|---|---|
| P/E Ratio | 29.1x | Adequate | Premium valuation |
| EV/Sales | 2.2x | Good | Attractive revenue multiple |
| FCF Yield | 23.8% | Excellent | Attractive cash return |
Sector Rankings
| Metric | Value | Percentile | vs Median |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 2.6% | Top 50% | - |
| Free Cash Flow Margin | 79.9% | Top 5% | - |
| Operating Margin | 4.7% | Top 50% | 1.0x above |
| Return on Equity (ROE) | 8.4% | Top 50% | - |
| P/E Ratio | 29.1x | N/A | - |
Rating Thresholds
Return on Invested Capital (ROIC)
Measures how efficiently a company uses its debt and equity capital to generate profits. ROIC above 15% typically indicates a competitive moat.
| Rating | Range | Interpretation |
|---|---|---|
| Excellent | > 20% | Exceptional capital efficiency, strong competitive moat |
| Good | 12% - 20% | Above-average returns, sustainable competitive position |
| Adequate | 8% - 12% | Around cost of capital, moderate competitive position |
| Warning | 4% - 8% | Below cost of capital, value may be eroding |
| Red flag | < 4% | Significant capital destruction, fundamental issues |
Current: 2.6% (Red flag - Top 50% of sector (median: 0.0%))
Free Cash Flow Margin
The percentage of revenue converted to free cash flow. Higher margins indicate stronger cash generation and business quality.
| Rating | Range | Interpretation |
|---|---|---|
| Excellent | > 20% | Strong cash generation, high-quality business |
| Good | 10% - 20% | Healthy cash conversion |
| Adequate | 5% - 10% | Moderate cash generation |
| Warning | 0% - 5% | Thin cash margins, capital intensive |
| Red flag | < 0% | Cash burn, potential liquidity concerns |
Current: 79.9% (Excellent - Top 5% of sector (median: 0.0%))
Debt to Equity Ratio
Total debt divided by shareholders' equity. Lower ratios indicate more conservative financing and reduced financial risk.
| Rating | Range | Interpretation |
|---|---|---|
| Excellent | < 0.3x | Conservative leverage, strong balance sheet |
| Good | 0.3x - 0.7x | Moderate leverage, healthy financial position |
| Adequate | 0.7x - 1.5x | Elevated leverage, monitor closely |
| Warning | 1.5x - 3.0x | High leverage, increased financial risk |
| Red flag | > 3.0x | Excessive leverage, potential distress risk |
Current: 0.0% (Excellent)
P/E Ratio (Price-to-Earnings)
Stock price divided by earnings per share. Lower P/E may indicate undervaluation, while higher P/E suggests growth expectations.
| Rating | Range | Interpretation |
|---|---|---|
| Excellent | < 15x | Attractively valued, potential opportunity |
| Good | 15x - 25x | Fair value for quality company |
| Adequate | 25x - 35x | Growth premium, justify with earnings growth |
| Warning | 35x - 50x | High expectations priced in |
| Red flag | > 50x or negative | Speculative valuation or losses |
Current: 29.1x (Adequate)
Free Cash Flow Yield
Free cash flow per share divided by stock price. Higher FCF yield indicates better cash return relative to valuation.
| Rating | Range | Interpretation |
|---|---|---|
| Excellent | > 8% | High cash return, potential value opportunity |
| Good | 5% - 8% | Solid cash yield |
| Adequate | 3% - 5% | Moderate cash return |
| Warning | 1% - 3% | Low cash yield, growth expectations |
| Red flag | < 1% | Minimal cash return to shareholders |
Current: 23.8% (Excellent)
Frequently Asked Questions
Q: What is Monte Rosa Therapeutics, Inc.'s Return on Invested Capital (ROIC)?
Monte Rosa Therapeutics, Inc. (GLUE) has a trailing twelve-month Return on Invested Capital (ROIC) of 2.6%. This compares above the sector median of 0.0%. An ROIC below 8% suggests the company may be destroying shareholder value.
Q: What is Monte Rosa Therapeutics, Inc.'s Free Cash Flow Margin?
Monte Rosa Therapeutics, Inc. (GLUE) has a free cash flow margin of 79.9%, generating $145.0 million in free cash flow over the trailing twelve months. A FCF margin above 20% indicates excellent cash conversion and a high-quality business model.
Q: Is Monte Rosa Therapeutics, Inc. stock overvalued or undervalued?
Monte Rosa Therapeutics, Inc. (GLUE) trades at a P/E ratio of 29.1x, which is above the sector median of N/A. The EV/Sales multiple is 2.2x. Free cash flow yield is 23.8%, which represents an attractive cash return to investors.
Q: What is Monte Rosa Therapeutics, Inc.'s revenue and earnings growth?
Monte Rosa Therapeutics, Inc. (GLUE) grew revenue by 1112.3% year-over-year. Double-digit revenue growth indicates strong demand and market share gains.
Q: How does Monte Rosa Therapeutics, Inc. compare to competitors in Healthcare?
Compared to other companies in Healthcare, Monte Rosa Therapeutics, Inc. (GLUE) shows: ROIC of 2.6% is above the sector median of 0.0% (Top 45%). FCF margin of 79.9% exceeds the sector median of 0.0% (Top 0% of sector). These rankings are based on MetricDuck's analysis of all Healthcare companies with available SEC filings.
Q: What warning signs should I watch for with Monte Rosa Therapeutics, Inc.?
Monte Rosa Therapeutics, Inc. (GLUE) shows no major financial warning signs based on current metrics. However, investors should always monitor: 1) Margin compression trends, 2) Cash flow consistency, 3) Debt levels relative to cash generation, and 4) Changes in competitive positioning.
Data Source: Data sourced from 10-Q filed 2025-11-06. TTM metrics as of Q3 2025.
Methodology: Financial metrics calculated from SEC 10-K and 10-Q filings using standardized formulas. Sector comparisons use peer group based on SIC code.
This analysis is for informational purposes only and does not constitute investment advice.